Sinopharm Tech Holdings Second Quarter 2024 Earnings: HK$0.003 loss per share (vs HK$0.061 profit in 2Q 2023)

Simply Wall St.03-02

Sinopharm Tech Holdings (HKG:8156) Second Quarter 2024 ResultsKey Financial Results Revenue: HK$14.9m (up 58% from 2Q 2023). Net loss: HK$533.0k (down by 105% from HK$11.0m profit in 2Q 2023). HK$...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2416198330?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/4211000-choice1-main-header/1585186648041","is_english":true,"pubTime":"2024-03-02 08:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2416198330","market":"nz","top_or_hot":-1,"title":"Sinopharm Tech Holdings Second Quarter 2024 Earnings: HK$0.003 loss per share (vs HK$0.061 profit in 2Q 2023)","media":"Simply Wall St.","content":"<div>\n<p>Sinopharm Tech Holdings (HKG:8156) Second Quarter 2024 ResultsKey Financial Results Revenue: HK$14.9m (up 58% from 2Q 2023). Net loss: HK$533.0k (down by 105% from HK$11.0m profit in 2Q 2023). HK$...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/consumer-services/hkg-8156/sinopharm-tech-holdings-shares/news/sinopharm-tech-holdings-second-quarter-2024-earnings-hk0003\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sinopharm Tech Holdings Second Quarter 2024 Earnings: HK$0.003 loss per share (vs HK$0.061 profit in 2Q 2023)</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSinopharm Tech Holdings Second Quarter 2024 Earnings: HK$0.003 loss per share (vs HK$0.061 profit in 2Q 2023)\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-03-02 08:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/hk/consumer-services/hkg-8156/sinopharm-tech-holdings-shares/news/sinopharm-tech-holdings-second-quarter-2024-earnings-hk0003><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sinopharm Tech Holdings (HKG:8156) Second Quarter 2024 ResultsKey Financial Results Revenue: HK$14.9m (up 58% from 2Q 2023). Net loss: HK$533.0k (down by 105% from HK$11.0m profit in 2Q 2023). HK$...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/consumer-services/hkg-8156/sinopharm-tech-holdings-shares/news/sinopharm-tech-holdings-second-quarter-2024-earnings-hk0003\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01099","symbol_name":"国药控股","start_time":0,"source_url":"https://simplywall.st/stocks/hk/consumer-services/hkg-8156/sinopharm-tech-holdings-shares/news/sinopharm-tech-holdings-second-quarter-2024-earnings-hk0003","article_id":"2416198330","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/4211000-choice1-main-header/1585186648041"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2416198330","pubTimestamp":1709338026,"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Sinopharm Tech Holdings ( HKG:8156 ) Second Quarter 2024 Results Key Financial Results Revenue: HK$14.9m (up 58% from...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"01099":"国药控股"},"translate_title":"国药科技控股2024年第二季度盈利：每股亏损0.003港元（2023年第二季度盈利0.061港元）","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01099":1},"content_text":"Sinopharm Tech Holdings (HKG:8156) Second Quarter 2024 ResultsKey Financial Results Revenue: HK$14.9m (up 58% from 2Q 2023). Net loss: HK$533.0k (down by 105% from HK$11.0m profit in 2Q 2023). HK$0.003 loss per share (down from HK$0.061 profit in 2Q 2023).  SEHK:8156 Earnings and Revenue History March 2nd 2024 All figures shown in the chart above are for the trailing 12 month (TTM) period Sinopharm Tech Holdings shares are up 13% from a week ago.   Risk Analysis You should learn about the   2 warning signs  we've spotted with Sinopharm Tech Holdings. Valuation is complex, but we're helping make it simple.Find out whether Sinopharm Tech Holdings is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.View the Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2416198330"}